Welcome to our dedicated page for Mereo Biopharma SEC filings (Ticker: MREO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mereo BioPharma Group plc (NASDAQ: MREO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other documents filed with the Securities and Exchange Commission. These filings offer primary-source information on Mereo’s financial condition, clinical development updates, and material corporate events.
Mereo’s Form 8-K filings, for example, have furnished press releases covering quarterly financial results, cash and cash equivalents, and recent corporate highlights. They also describe key clinical milestones, such as the progress of the Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta, Data Monitoring Committee recommendations to proceed to final analysis, and subsequent top-line results. Other 8-K reports outline developments in the company’s pipeline, including partnering activities and regulatory designations for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease.
Through this page, users can follow how Mereo reports its operating performance, research and development spending, and capital structure over time via its SEC submissions. Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand the implications of new 8-Ks, 10-Ks or 10-Qs without reading every line.
Investors interested in MREO can use the filings page to monitor material updates on clinical programs, financing, and corporate agreements as they are reported to the SEC. Real-time access, combined with AI-generated explanations, supports efficient review of Mereo BioPharma’s regulatory history and ongoing disclosure record.
Jacquet Pierre reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group plc director Pierre Jacquet reported equity awards rather than open‑market trades. He received share options for 66,000 shares at a price of $0.00 per share and 106,848 deferred restricted stock units, both recorded as direct beneficial ownership.
The options vest in substantially equal monthly installments over one year from the February 26, 2026 grant date. The deferred restricted stock units are granted in lieu of annual cash compensation, vest monthly over the following plan year, and are generally settled in American Depositary Shares about 180 days after separation of service. Each ADS represents five ordinary shares.
Mereo BioPharma Group plc director Marc J. Yoskowitz reported equity compensation awards. He received share options covering 66,000 shares at an exercise price of $0.0000 per share, classified as a grant or award acquisition.
He was also granted 96,163 deferred restricted stock units, which are provided in the form of American Depositary Shares instead of annual cash compensation. The options vest in substantially equal monthly installments over one year from the February 26, 2026 grant date, while the deferred restricted stock units vest in substantially equal monthly installments over the plan year and are generally settled in ADSs 180 days after separation of service.
Shames Daniel reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group plc director Daniel Shames reported receiving new equity awards. On February 26, 2026, he was granted 66,000 share options and 96,163 deferred restricted stock units as compensation. The options vest in substantially equal monthly installments over one year from the grant date.
The deferred restricted stock units are granted in the form of American Depositary Shares instead of annual cash compensation for non-executive directors and also vest in substantially equal monthly installments over the plan year. Each ADS represents five ordinary shares of Mereo BioPharma Group plc.
Ekblom Anders reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group plc director Anders Ekblom reported equity awards that increase his potential ownership stake. He received share options for 66,000 shares at a price of
The options vest in substantially equal monthly installments over one year from the grant date. The deferred restricted stock units were elected in lieu of annual cash compensation and also vest in substantially equal monthly installments over the plan year, with settlement in American Depositary Shares, where each ADS represents five ordinary shares, generally 180 days after separation of service.
Mereo BioPharma Group plc director Jeremy Bender reported equity awards rather than open-market trades. On February 26, 2026, he received share options for 66,000 shares at a price of $0.00 per share, vesting in substantially equal monthly installments over one year from the grant date.
He also acquired 117,533 deferred restricted stock units, granted in lieu of annual cash compensation, which vest in substantially equal monthly installments over the plan year following the grant date. Each American Depositary Share represents five ordinary shares, and payment of these deferred units in ADSs will generally occur 180 days after separation of service.
PAKIANATHAN DEEPIKA reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group plc director Deepika Pakianathan was granted share options covering 66,000 shares on February 26, 2026. The options have a right to buy the company’s shares at a price of $0.0000 per share.
The grant vests in substantially equal monthly installments over one year from the February 26, 2026 grant date, meaning portions of the award become exercisable each month during that period.
Jenkins Annalisa reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group director Annalisa Jenkins received new equity-based compensation awards. She was granted 66,000 share options with a right to buy shares at no initial cost and 106,848 deferred restricted stock units, both dated February 26, 2026.
The share options vest in substantially equal monthly installments over one year from the grant date. The deferred restricted stock units were elected in lieu of annual cash compensation, vest monthly over the following plan year, and are generally settled in American Depositary Shares about 180 days after service ends.
WYZGA MICHAEL S reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group plc director Michael S. Wyzga reported receiving a grant of 66,000 share options on February 26, 2026. These options are a right to buy shares and were awarded for no cash payment at grant. The award vests in substantially equal monthly installments over one year from the February 26, 2026 grant date. Each American Depositary Share represents five ordinary shares of the company.
Mereo BioPharma Group plc received an amended Schedule 13G/A from investment entities affiliated with Northpond, including Northpond Ventures funds and Michael P. Rubin, stating they beneficially own 0 ordinary shares, representing 0.0% of the class, as of December 31, 2025.
The filing clarifies that CUSIP 589492107 applies to the American Depositary Shares, with each ADS representing five ordinary shares. The reporting persons also certify that the securities referenced were not acquired or held for the purpose of changing or influencing control of Mereo BioPharma.
Mereo BioPharma Group plc has received a Nasdaq notice that its American Depositary Shares have not met the required minimum bid price of
The company has 180 calendar days, until